BioXcel Therapeutics, Inc. (BTAI): Price and Financial Metrics

BioXcel Therapeutics, Inc. (BTAI): $15.61

0.10 (+0.64%)

POWR Rating

Component Grades













BTAI Stock Price Chart Interactive Chart >

Price chart for BTAI

BTAI Price/Volume Stats

Current price $15.61 52-week high $24.57
Prev. close $15.51 52-week low $8.80
Day low $15.32 Volume 54,000
Day high $15.77 Avg. volume 466,807
50-day MA $12.44 Dividend yield N/A
200-day MA $14.35 Market Cap 437.42M

BioXcel Therapeutics, Inc. (BTAI) Company Bio

BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent designed for the treatment of prostate and pancreatic cancers. It is also developing BXCL502, a novel approach to the treatment of symptoms resulting from neurological disorders; and BXCL702, an immuno-oncology agent for hematological malignancies. The company was founded in 2017 and is based in Branford, Connecticut. BioXcel Therapeutics, Inc. is a subsidiary of BioXcel Corporation.

BTAI Latest News Stream

Event/Time News Detail
Loading, please wait...

BTAI Latest Social Stream

Loading social stream, please wait...

View Full BTAI Social Stream

Latest BTAI News From Around the Web

Below are the latest news stories about BIOXCEL THERAPEUTICS INC that investors may wish to consider to help them evaluate BTAI as an investment opportunity.

Is This Soaring Growth Stock a Buy?

BioXcel remains deep in the red for the year, but ongoing developments have helped fuel the company's recent run. It has just one product on the market, Igalmi, a sublingual film that treats acute agitation (intense anxiety often accompanied by excessive or aggressive activity) in patients with schizophrenia and bipolar disorder 1 or 2. In the third quarter, the company reported revenue of just $137,000.

Yahoo | November 20, 2022

BioXcel Therapeutics to Present at Two Upcoming Investor Conferences

NEW HAVEN, Conn., Nov. 14, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that Vimal Mehta, Ph.D., Founder and Chief Executive Officer, and Matt Wiley, Chief Commercial Officer, will participate in fireside chats at two upcoming investor conferences. Management will discuss the Company’s neuroscience and immuno-onco

Yahoo | November 14, 2022

BTAI: Positive Early Metrics for IGALMI™ Launch…

By David Bautz, PhD NASDAQ:BTAI READ THE FULL BTAI RESEARCH REPORT Business Update Commercial Day Highlights Positive Early Launch Metrics for IGALMI™ On October 18, 2022, BioXcel Therapeutics, Inc. (NASDAQ:BTAI) hosted a Commercial Day presentation to provide an update on the recent launch of IGALMI™, which is approved for the acute treatment of agitation associated with schizophrenia or bipolar

Yahoo | November 14, 2022

BioXcel Therapeutics Reports Third Quarter 2022 Financial Results and Recent Operational Highlights

IGALMI™ (dexmedetomidine) well-positioned for growth in 2023 based on increasing market access, efficient targeting, favorable market drivers, and sales force expansion in all major U.S. geographies Top-line pivotal data for TRANQUILITY II trial investigating BXCL501 for Alzheimer’s-related agitation expected in 1H 2023 Top-line pivotal data for SERENITY III trial investigating at-home use of BXCL501 for acute treatment of bipolar and schizophrenia-related agitation expected in 1H 2023 Completed

Yahoo | November 10, 2022

Mizuho Securities Sticks to Their Buy Rating for Bioxcel Therapeutics (BTAI)

E ratio of -2.81.

Brian Anderson on TipRanks | November 9, 2022

Read More 'BTAI' Stories Here

BTAI Price Returns

1-mo 30.74%
3-mo 13.61%
6-mo N/A
1-year -30.87%
3-year 145.83%
5-year N/A
YTD -23.22%
2021 -56.00%
2020 216.22%
2019 278.50%
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7988 seconds.